<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_MIT_REST-results skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:MIT/REST-results</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><DIV class="navdiv-wrapper"><DIV class="navdiv"><UL><LI><A href="https://2017.igem.org/Team:MIT/Team">ABOUT US</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/Team">Team</A><A href="https://2017.igem.org/Team:MIT/Attributions">Attributions</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/AS">BACKGROUND</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/AS">Alternative Splicing</A><A href="https://2017.igem.org/Team:MIT/CRISPR">CRISPR</A><A href="https://2017.igem.org/Team:MIT/RBPs">RNA Binding Proteins</A><A href="https://2017.igem.org/Team:MIT/REST">REST</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/project">PROJECT</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/GuidesandASOs">Guides and ASOs</A><A href="https://2017.igem.org/Team:MIT/mk-FF4">mKate-FF4</A><A href="https://2017.igem.org/Team:MIT/2mk-HBG">2 Exon mKate HBG</A><A href="https://2017.igem.org/Team:MIT/3mk-HBG">3 Exon mKate HBG</A><A href="https://2017.igem.org/Team:MIT/3mk-DF">3 Exon Dual Fluorescence</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/notebook">LAB WORK</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/parts">Parts/Improved Parts</A><A href="https://2017.igem.org/Team:MIT/protocols">Protocols</A><A href="https://2017.igem.org/Team:MIT/notebook">Notebook</A><A href="https://2017.igem.org/Team:MIT/Future-Work">Future Work</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/Model">MODELLING</A></LI><LI><A href="#">HUMAN PRACTICES</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/HP/Gold_Integrated">Integrated HP</A><A href="https://2017.igem.org/Team:MIT/Engagement">Public Engagement</A><A href="https://2017.igem.org/Team:MIT/Collaborations">Collaborations</A><A href="https://2017.igem.org/Team:MIT/InterLab">InterLab</A></DIV></LI><LI><A href="https://2017.igem.org/Team:MIT/award">AWARDS</A><DIV class="submenu"><A href="https://2017.igem.org/Team:MIT/HP/Silver">HP Silver</A><A href="https://2017.igem.org/Team:MIT/HP/Gold_Integrated">HP Gold</A><A href="https://2017.igem.org/Team:MIT/Engagement">Education &amp; Public Engagement</A><A href="https://2017.igem.org/Team:MIT/Model">Model</A><A href="https://2017.igem.org/Team:MIT/Part_Collection">Parts Collection</A></DIV></LI></UL></DIV></DIV><H1 style="color:#ff0000; text-align: center; font-size: 40px; line-height: 40px;">Experiments with Small Cell Lung Cancer</H1><P>Once we had decided on a disease model, namely Small Cell Lung Cancer, we needed an in-vivo way of testing our system. To this end we obtained the H82 Cell line from ATCC.</P><H2 style="color:#ffffff; background-color:#ff0000; -moz-border-radius: 15px; -webkit-border-radius: 15px; padding:15px; text-align: center"> Preliminary Results </H2><H3> Viafect Optimization</H3><P>The first thing we had to ensure was that we were able to get DNA into the new cell line. We performed a Viafect optimization to test what our ratio of plasmid to transfection reagent should be. We transfected constitutively expressed BFP and reagent at ratios 1:1, 1:2, 1:3 and 1:4.</P><CENTER><H3>Viafect Optimization</H3></CENTER><P><I>Ratio of Viafect:BFP vs. the blue fluorescent output (AU) of the H82s</I></P><P>We see the most fluorescent output at a 1:3 ratio of Viafect:BFP. <STRONG>Moving forward, we transfected at a 1:3 ratio.</STRONG></P><H3>RT-qPCR</H3><P>To analyze the effectiveness of our RNA binding protein system on the alteration of the splicing event of REST in H82 Small Cell Lung Cancer cells, we conducted to Real-Time PCR on H82 SCLC cell line samples, transfected with the dCas113a along with the constructed REST1, REST2, REST3, REST4, REST5 and HBG (random) Guides respectively. The RT-qPCR experiments allow us to assess the amounts of each RNA isoform present in the H82 cells. We have carried out three selective amplifications for each of the 6 samples above:
<OL><LI>First Round of Amplification is selective Amplification for REST using primers spanning the alternative exon junction but not the exon itself.</LI><LI>Second Round of amplification for REST4 is by using primers spanning the alternative exon.</LI><LI>Third round of amplification is the selective amplification of Beta Actin gene as a housekeeping gene</LI></OL></P><P>We can see from these results that REST Guide 2 and REST Guide 4 performed the best.</P></DIV></DIV></DIV></DIV></DIV></BODY></HTML>